Beauty’s next $2B market is the Ozempic face

When a side effect gets a nickname, marketers should pay attention. ‘Ozempic face’ now describes the hollowing and sagging some people notice after rapid weight loss on GLP-1 drugs, and beauty companies are building a pipeline around that anxiety.

The opportunity is not small. Pfizer estimates the obesity drug market could reach $150 billion in annual sales by 2030. Boston Consulting Group’s 2025 estimates suggest revenue from related clinical aesthetic treatments could climb from about $700 million to $2 billion over five years.

A need looking for a product

Galderma, Natura and L’Oreal are all testing or positioning products for GLP-1 users. Galderma, 20% owned by L’Oreal, studied how its Sculptra and Restylane lines perform on skin changes tied to weight-loss drugs. L’Oreal says it is running separate studies on GLP-1 users because the segment is becoming significant globally. Natura is testing with GLP-1 users and exploring formats beyond creams.

• 53% of US aesthetics clinics expect new patients from prescription weight-loss medications.
• 43% expect these medications to drive demand for facial-change treatments.
• Most GLP-1 users are 50-64, so ageing and menopause can also explain volume loss.

The catch for beauty marketers

The inviting story, that a drug is ruining faces and a cream can fix it, is too simple. Consultant dermatologist Beibei Du-Harpur put it directly: ‘The drug doesn’t melt your collagen.’ Rapid, unsustainable weight loss is the likelier trigger. Other clinicians note that many patients are perimenopausal or postmenopausal, making collagen and estrogen changes part of the picture.

There is also a hard product limit. Topical creams may improve skin quality because they can reach the epidermis and upper dermis, but they cannot reposition facial fat or tighten ligamental structure. Injectables and fillers are closer to the actual loss, because volume disappears from the fat layer below the dermis.

What marketers should do

Frame the category around the rapid weight-loss journey, not the drug. A useful lens is Jobs to Be Done: after rapid weight loss, people are hiring products for two jobs, visible skin quality and structural volume. No single cream is hired for both. Educate honestly about what topicals can and cannot do, and position fillers or skin-quality products as distinct jobs. That builds trust in a segment where consumers are already worried and sceptical of overclaiming.

Source: ETRetail.com